Question 1

What is GenePHIT?

Accepted Answer

GenePHIT is a Other.

Question 2

How often does GenePHIT appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was GenePHIT first tracked by Ergen?

Accepted Answer

First tracked on Apr 01, 2026.

Question 4

When was GenePHIT last mentioned in news?

Accepted Answer

Last active on Apr 01, 2026.

Question 5

What is GenePHIT's current news sentiment?

Accepted Answer

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is GenePHIT in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving GenePHIT?

Accepted Answer

AskBio completes AB-1002 trial enrollment (Apr 01, 2026, 6 articles).

Question 8

How did the "AskBio completes AB-1002 trial enrollment" event impact GenePHIT?

Accepted Answer

GenePHIT is the Phase 2 clinical trial for AB-1002, which has completed enrollment. Its successful completion and positive results are crucial for the development of AB-1002.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.